Dr. Matthew G. Davis, MD
Family Medicine (Family Medicine Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NY license 189975
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $2,333 in total to this clinician.
| Pfizer Inc. | $2,333 |
|---|
| Travel and Lodging | $1,817 |
|---|---|
| Food and Beverage | $516 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 23, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $1,259 |
| Pfizer Inc. May 24, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $257 |
| Pfizer Inc. May 24, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $257 |
| Pfizer Inc. May 30, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Chicago, IL · in-kind | $44.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 45 industry-funded studies in 2025, from 19 companies. The companies reported $6,515,667 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A phase 1 randomized and phase 2 study to evaluate the safety tolerability immunogenicity and immunopersistence of a clostridioides difficile vaccine administered in a 2DOSE regimen with novel adjuvants in healthy adults
Pfizer Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A phase 2A randomized doubleblind sponsoropen placebocontrolled parallel group doseranging study of PF07976016 to assess safety and efficacy in adult participants with obesity
Pfizer Inc. - Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity
Genentech, Inc. - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc. · Completed · NCT05831111 - A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929066 - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
ModernaTX, Inc. · Completed · NCT05992935
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.